Efanesoctocog alfa for treating and preventing bleeding in people with haemophilia A who have been previously treated

Efanesoctocog alfa is currently in clinical development for the treatment and prevention (prophylaxis) of bleeding episodes in patients with haemophilia A. Haemophilia A is a genetic bleeding disorder caused by a deficiency or absence of a blood clotting factor, called factor VIII (eight). This causes poor blood clotting, which results in difficulty in stopping the flow of blood from a wound, causing prolonged bleeding. Current therapy includes preventative (prophylactic) treatment where medicine is used to prevent bleeding, or on-demand treatment, where medicine is used to treat prolonged bleeding. Haemophilia A treatments includes regular injections of factor VIII and/or various types of clotting factor medicines. However, von Willebrand factor (VWF), another clotting factor, limits factor VIII circulation in the blood.